South Korea
· Delayed Price · Currency is KRW DongKook Pharmaceutical Company Description
DongKook Pharmaceutical Co., Ltd. produces and sell pharmaceutical products in South Korea and internationally.
The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, and cosmetics.
Its pipeline includes DKF-310, which is in preclinical trials for the treatment of dementia; DKM-413, used for anesthetic; DKF-361, used to treat hypertension; DKF-325, an anticoagulant; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, that is in clinical studies, indicated for benign prostatic hyperplasia; DKF-340, a nonsteroidal anti-inflammatory drugs; DKM-415, indicated for synovial fluid replacement; DKF-334 and DKF-335 to treat osteoporosis; and DKF-363, for treatment of respiratory inflammation.
In addition, the company develops DKB-119 and DKM-410, a biomaterial for tissue restoration; as well as develops new drugs for obesity and diabetes that is in preclinical studies.
The company was formerly known as UEC & Co., Ltd. and changed its name to DongKook Pharmaceutical Co., Ltd. in March 1982.
The company was founded in 1968 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 1968 |
| Industry | Pharmaceutical Preparations |
| Employees | 1,116 |
Contact Details
Address: 715 Yeongdong-daero Seoul South Korea | |
| Phone | 82 2 2191 9800 |
| Website | dkpharm.co.kr |
Stock Details
| Ticker Symbol | 086450 |
| Exchange | KOSDAQ |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2834 |